Success Metrics

Clinical Success Rate
85.4%

Based on 35 completed trials

Completion Rate
85%(35/41)
Active Trials
7(13%)
Results Posted
37%(13 trials)
Terminated
6(11%)

Phase Distribution

Ph phase_1
8
14%
Ph not_applicable
13
23%
Ph phase_2
10
18%
Ph phase_4
7
13%
Ph early_phase_1
3
5%
Ph phase_3
12
21%

Phase Distribution

11

Early Stage

10

Mid Stage

19

Late Stage

Phase Distribution53 total trials
Early Phase 1First-in-human
3(5.7%)
Phase 1Safety & dosage
8(15.1%)
Phase 2Efficacy & side effects
10(18.9%)
Phase 3Large-scale testing
12(22.6%)
Phase 4Post-market surveillance
7(13.2%)
N/ANon-phased studies
13(24.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

79.5%

35 of 44 finished

Non-Completion Rate

20.5%

9 ended early

Currently Active

7

trials recruiting

Total Trials

56

all time

Status Distribution
Active(7)
Completed(35)
Terminated(9)
Other(5)

Detailed Status

Completed35
Recruiting6
Terminated6
unknown4
Withdrawn3
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
56
Active
7
Success Rate
85.4%
Most Advanced
Phase 4

Trials by Phase

Early Phase 13 (5.7%)
Phase 18 (15.1%)
Phase 210 (18.9%)
Phase 312 (22.6%)
Phase 47 (13.2%)
N/A13 (24.5%)

Trials by Status

completed3563%
active_not_recruiting12%
recruiting611%
terminated611%
suspended12%
unknown47%
withdrawn35%

Recent Activity

Clinical Trials (56)

Showing 20 of 56 trialsScroll for more
NCT04600115Early Phase 1

New MRI Methods Applied to Heart Failure With Preserved Ejection Fraction (HFpEF)

Recruiting
NCT03218137Phase 4

Use of Adenosine to Determine the Electrophysiological Mechanism of Premature Ventricular Contractions

Recruiting
NCT06993038Phase 4

Adenosine vs Diltiazem for Treatment of SVT in the ED

Recruiting
NCT03505736

Stress Test in Detecting Heart Damage in Premenopausal Women With Stage I-III Breast Cancer

Completed
NCT03537586Not Applicable

A Single Center Diagnostic, Cross-sectional Study of Coronary Microvascular Dysfunction

Active Not Recruiting
NCT06578234Phase 4

Hyperemic mYocardial Perfusion by adEnosine at diffeRent Doses

Recruiting
NCT06717685Phase 3

Efficacy of Adenosine as Compared to Verapamil in Paroxysmal Supraventricular Tachycardia (pSVT) Patients

Recruiting
NCT04666454Phase 4

BROKEN-SWEDEHEART- Optimized Pharmacological Treatment for Broken Heart (Takotsubo) Syndrome.

Recruiting
NCT03557385Phase 4

Adenosine Contrast CorrELations in Evaluating RevAscularizaTION

Completed
NCT05014061Phase 3

Adenosine's Effect on STunning Resolution in Acute Myocardial Infarction

Withdrawn
NCT04588441Phase 2

The ARCTIC Trial: Aerosolized Inhaled Adenosine Treatment in Patients With Acute Respiratory Distress Syndrome (ARDS) Caused by COVID-19

Withdrawn
NCT04577443Not Applicable

The Effect of Adenosine on Cranial Hemodynamic, Headache and Migraine Induction Properties.

Completed
NCT03236311Phase 2

A Dose Titration Study to Assess the Effects of SAR407899 in Patients With MVA and/or Persistent Stable Angina Despite Angiographically Successful PCI

Terminated
NCT03738943Early Phase 1

Pyridoxine, P2 Receptor Antagonism, and ATP-mediated Vasodilation in Young Adults

Completed
NCT04392362Phase 3

A Trial to Compare American Heart Association (AHA) and Simple (SIM)Method to Give Adenosine to Treat Supra-ventricular Tachycardia (SVT)

Completed
NCT04699110Phase 4

Adrenaline for the Treatment of No-Reflow in Normotensive Patients

Completed
NCT04203368Not Applicable

Adenosine Versus Verapamil for Management of Supraventricular Tachycardia Post- Coronary Artery Bypass Grafting

Completed
NCT03249272Phase 4

Microvascular Dysfunction in Nonischemic Cardiomyopathy: Insights From CMR Assessment of Coronary Flow Reserve

Terminated
NCT02608944Not Applicable

Comparison of Quantitative MRI Perfusion Methods With Quantitative PET Perfusion Imaging

Withdrawn
NCT00179010Phase 1

AMP as a Better Delivery System of Adenosine

Terminated

Drug Details

Intervention Type
DRUG
Total Trials
56